plitidepsin (aplidine)

07/16/2021 - "Preliminary findings in hospitalized COVID-19 patients, have suggested potential safety and efficacy of plitidepsin, in terms of viral load reduction and clinical resolution. "
01/01/2023 - "The APLICOV-PC study assessed the safety and preliminary efficacy of plitidepsin in hospitalized adult patients with COVID-19. "
01/01/2021 - "We demonstrate the in vivo efficacy of plitidepsin treatment in two mouse models of SARS-CoV-2 infection with a reduction of viral replication in the lungs by two orders of magnitude using prophylactic treatment. "
01/01/2022 - "Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19."
10/01/2023 - "Outcomes and clinical characteristics of the compassionate use of plitidepsin for immunocompromised adult patients with COVID-19."

06/01/2009 - "Phase I/II clinical trials of plitidepsin yielded promising results of anticancer activity in patients with cancer. "
01/29/2019 - "The efficacy of these new plitidepsin-containing carriers was evaluated in four cancer cell-lines and they showed similar anticancer activity to the current standard drug formulation."
12/01/2019 - "As previous report has indicated that the aplidin could inhibit the LMW-PTP, and thus, the relevant cancer caused by the abnormal regulation of the LMW-PTP could be remission. "
10/25/2017 - "The presented method was successfully applied in a mass balance study with plitidepsin in patients with advanced cancer."
10/25/2017 - "Plitidepsin is an anti-cancer drug currently evaluated in phase I/II/III clinical trials. "

01/01/2019 - "Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma."
04/01/2014 - "Plitidepsin is an antineoplasic currently in clinical evaluation in a phase III trial in multiple myeloma (ADMYRE). "
03/08/2023 - "Consistently, eEF1A has proven to be targeted by a wide assortment of small molecules with excellent anticancer activity, among which plitidepsin has been granted approval for the treatment of multiple myeloma. "
01/01/2021 - "Plitidepsin, a repurposed drug developed for the treatment of multiple myeloma, targets the host translation cofactor eEF1A. "
05/01/2020 - "Plitidepsin to treat multiple myeloma."

11/01/2009 - "As sensitivity to the drug varies between cell lines and fresh leukemia samples, we performed studies on transport of plitidepsin in leukemia and lymphoma cell lines to determine the mechanism of uptake. "
05/15/2008 - "Consecutive cohorts of patients with metastatic solid tumors or non-Hodgkin's lymphomas were to be treated at escalating doses of plitidepsin in a conventional phase I study including pharmacokinetic analyses of plitidepsin in plasma, whole blood, and blood cell pellets. "
04/01/2003 - "Aplidin increases sensitivity to treatment in leukemia and lymphoma cells."
03/01/2008 - "Another example is aplidine from the Mediterranean tunicate Aplidium albicans, with a broad spectrum activity against various types of cancers, such as colorectal, lymphoma, thyroid and renal cancers. "
12/01/2011 - "Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas."

07/01/2003 - "In conclusion, we show that aplidin has selective cytotoxicity in vitro towards childhood leukemia cells and generally lacks crossresistance with other known cytotoxic drugs, which warrants clinical studies."
12/01/2007 - "Moreover, mutant MOLT-4, human leukemia cells lacking functional mitochondria, were found to be resistant to Aplidin. "
11/01/2004 - "Aplidine is a potent pro-apoptotic inducer in human leukemia and has antiangiogenic properties. "
12/01/2007 - "The efficacy of the combination of Aplidin and araC is currently being evaluated in clinical phase I/II program for the treatment of patients with relapsed leukemia and high-grade lymphoma."
10/01/2012 - "The aim of this study was to evaluate the effect of Aplidin in chronic lymphocytic leukemia (CLL), the most common leukemia in the adult. "